Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
The Unity-CLL trial shows ublituximab plus umbralisib conferring an unexpected progression-free survival benefit.
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.